Skip to main content

Advertisement

SpringerLink
Log in

Management of Symptomatic Intracranial Atherosclerotic Stenosis

  • Cerebrovascular Disorders (Dara G. Jamieson, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

This review addresses the current evidence of epidemiologic and therapeutic strategies in patients with intracranial atherosclerotic stenosis (ICAS).

Recent findings

There is a considerable number of patients with ICAS worldwide, especially in Asia. Modern neuroimaging techniques have improved assessment lately and they are providing insight into ICAS-related mechanisms causing cerebrovascular ischaemic events. Several studies have investigated vascular risk factors for ICAS, primarily in Asians. Vascular risk factors not only facilitate the occurrence of ICAS, but their optimal management is linked to better outcome. Antithrombotic therapies also are a crucial prevention measure in these patients. Nevertheless, under best medical therapy, a considerable recurrence rate of cerebrovascular events has been reported. Thus, it has been investigated whether endovascular therapy or surgery are safe and beneficial options in patients with ICAS. In the future, optimal best medical therapy including novel drugs and careful patient selection for interventional therapy, differentiating the underlying pathophysiological mechanism of cerebrovascular ischaemic events and identifying characteristics of ICAS will be important. Improved endovascular devices and techniques might favour better outcome as well.

Summary

Current recommendations for therapeutic strategies in patients with ICAS include best medical therapy, optimal management of vascular risk factors and antithrombotic therapy. Endovascular and surgical therapy can be of benefit in selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Manzano JJ, De Silva DA, Pascual JL, Chang HM, Wong MC, Chen CP. Associations of ankle-brachial index (ABI) with cerebral arterial disease and vascular events following ischemic stroke. Atherosclerosis. 2012;223:219–22. https://doi.org/10.1016/j.atherosclerosis.2012.04.009.

    Article  CAS  PubMed  Google Scholar 

  2. Resch JA, Loewenson RB, Baker AB. Physical factors in the pathogenesis of cerebral atherosclerosis. Stroke. 1970;1(2):77–85. https://doi.org/10.1161/01.str.1.2.77.

    Article  CAS  PubMed  Google Scholar 

  3. McCridle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the young, with the council on cardiovascular nursing. Circulation. 2007;115:1948–67. https://doi.org/10.1161/CIRCULATIONAHA.107.181946.

    Article  Google Scholar 

  4. Gutierrez J, Elkind MSV, Virmani R, Goldman J, Honig L, Morgello S, et al. A pathological perspective on the natural history of cerebral atherosclerosis. Int J Stroke. 2015;10(7):1074–80. https://doi.org/10.1111/ijs.12496.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kimura H, Takao M, Suzuki N, Kanemaru K, Mihara B, Murayama S. Pathologic study of intracranial large artery atherosclerosis in 7260 autopsy cases. J Stroke Cerebrovasc Dis. 2017;26(12):2821–7. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.056.

    Article  PubMed  Google Scholar 

  6. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832–44. https://doi.org/10.1161/CIRCULATIONAHA.106.676890.

    Article  CAS  PubMed  Google Scholar 

  7. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–36. https://doi.org/10.1161/CIRCRESAHA.115.306301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sun R, Xiao L, Duan S. High expression of ubiquitin conjugates and NF-κB in unstable human intracranial atherosclerotic plaques. J Cell Physiol. 2012;227(2):784–8. https://doi.org/10.1002/jcp.22790.

    Article  CAS  PubMed  Google Scholar 

  9. Masuoka T, Hayashi N, Hori E, Kuwayama N, Ohtani O, Endo S. Distribution of internal elastic lamina and external elastic lamina in the internal carotid artery: possible relationship with atherosclerosis. Neurol Med Chir (Tokyo). 2010;50(3):179–82. https://doi.org/10.2176/nmc.50.179.

    Article  Google Scholar 

  10. Routsonis KG, Stamboulis E, Christodoulaki M. Anomalies of the circle of Willis and atherosclerosis. Vasc Surg. 1973;7:141–5. https://doi.org/10.1177/153857447300700301.

    Article  CAS  PubMed  Google Scholar 

  11. Ovbiagele B, Saver JL, Lynn MJ, Chimowitz M, WASID Study Group. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology. 2006;66(9):1344–9. https://doi.org/10.1212/01.wnl.0000210530.46058.5c.

    Article  PubMed  Google Scholar 

  12. Lei C, Wu B, Liu M, Chen Y. Risk factors and clinical outcomes associated with intracranial and extracranial atherosclerotic stenosis acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(5):1112–7. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.09.024.

    Article  PubMed  Google Scholar 

  13. Kim JS, Nah HW, Park SM, Kim SK, Cho KH, Lee J, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke. 2012;43(12):3313–8. https://doi.org/10.1161/STROKEAHA.112.658500.

    Article  CAS  PubMed  Google Scholar 

  14. • Ma YH, Leng XY, Dong Y, Xu W, Cao XP, Ji X, et al. Risk factors for intracranial atherosclerosis: a systematic review and meta-analysis. Atherosclerosis. 2019;281:71–7. https://doi.org/10.1016/j.atherosclerosis.2018.12.015. A recent meta-analysis designed to investigate the risk factors for ICAS.

    Article  CAS  PubMed  Google Scholar 

  15. Mechia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754–832. https://doi.org/10.1161/STR.0000000000000046.

    Article  Google Scholar 

  16. Kim YD, Choi HY, Jung YH, Nam CM, Yang JH, Cho HJ, et al. Classic risk factors for atherosclerosis are not major determinants for location of extracranial or intracranial cerebral atherosclerosis. Neuroepidemiology. 2009;32(3):201–7. https://doi.org/10.1159/000195690.

    Article  PubMed  Google Scholar 

  17. Rincon F, Sacco RL, Kranwinkel G, Xu Q, Paik MC, Boden-Albala B, et al. Incidence and risk factors of intracranial atherosclerotic stroke: the northern Manhattan stroke study. Cerebrovasc Dis. 2009;28:65–71. https://doi.org/10.1159/000219299.

    Article  PubMed  PubMed Central  Google Scholar 

  18. D'Armiento FP, Bianchi A, de Nigris F, Capuzzi DM, D'Armiento MR, Crimi G, et al. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke. 2001;32(11):2472–9. https://doi.org/10.1161/hs1101.098520.

    Article  CAS  PubMed  Google Scholar 

  19. People's Republic of China—United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China. Baseline report from the P.R.C.-U.S.A. Collaborative Study. Circulation. 1992;85(3):1083–96. https://doi.org/10.1161/01.cir.85.3.1083.

    Article  Google Scholar 

  20. McGruder HF, Malarcher AM, Antoine TL, Greenlund KJ, Croft JB. Racial and ethnic disparities in cardiovascular risk factors among stroke survivors: United States 1999 to 2001. Stroke. 2004;35(7):1557–61. https://doi.org/10.1161/01.STR.0000130427.84114.50.

    Article  PubMed  Google Scholar 

  21. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and south Asians. Int J Obes Relat Metab Disord. 2001;25(9):1327–31. https://doi.org/10.1038/sj.ijo.0801723.

    Article  CAS  PubMed  Google Scholar 

  22. Boehme AK, Ranawat P, Luna J, Kamel H, Elkind MS. Risk of acute stroke after hospitalization for sepsis: a case-crossover study. Stroke. 2017;48(3):574–80. https://doi.org/10.1161/STROKEAHA.116.016162.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Consoli D, Vidale S, Aguglia U, Bassi P, Cavallini A, Galati F, et al. Previous infection and the risk of ischaemic stroke in Italy: the IN2 study. Eur J Neurol. 2015;22(3):514–9. https://doi.org/10.1111/ene.12601.

    Article  CAS  PubMed  Google Scholar 

  24. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36–40.

    PubMed  Google Scholar 

  25. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914.

    Article  CAS  PubMed  Google Scholar 

  26. White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation. 2005;111(10):1327–31. https://doi.org/10.1161/01.CIR.0000157736.19739.D0.

    Article  PubMed  Google Scholar 

  27. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke. 1995;26(1):14–20. https://doi.org/10.1161/01.str.26.1.14.

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese intracranial atherosclerosis (CICAS) study. Stroke. 2014;45(3):663–9. https://doi.org/10.1161/STROKEAHA.113.003508.

    Article  PubMed  Google Scholar 

  29. Wong KS, Li H, Chan YL, Ahuja A, Lam WW, Wong A, et al. Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke. 2000;31(11):2641–7. https://doi.org/10.1161/01.str.31.11.2641.

    Article  CAS  PubMed  Google Scholar 

  30. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke. 2011;42(10):2883–90. https://doi.org/10.1161/STROKEAHA.110.609370.

    Article  CAS  PubMed  Google Scholar 

  31. López-Cancio E, Dorado L, Millán M, Reverté S, Suñol A, Massuet A, et al. The Barcelona-asymptomatic intracranial atherosclerosis (AsIA) study: prevalence and risk factors. Atherosclerosis. 2012;221(1):221–5. https://doi.org/10.1016/j.atherosclerosis.2011.12.020.

    Article  CAS  PubMed  Google Scholar 

  32. Bos D, van der Rijk MJ, Geeraedts TE, Hofman A, Krestin GP, Witteman JC, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke. 2012;43:1878–84. https://doi.org/10.1161/STROKEAHA.111.648667.

    Article  PubMed  Google Scholar 

  33. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke. 2006;1:158–9.

    Article  PubMed  Google Scholar 

  34. Borozan PG, Schuler JJ, LaRosa MP, Ware MS, Flanigan DP. The natural history of isolated carotid siphon stenosis. J Vasc Surg. 1984;1(6):744–9. https://doi.org/10.1067/mva.1984.avs0010744.

    Article  CAS  PubMed  Google Scholar 

  35. Ovbiagele B, Cruz-Flores S, Lynn MJ, Chimowitz MI. Warfarin-aspirin symptomatic intracranial disease (WASID) study group. Early stroke risk after transient ischemic attack among individuals with symptomatic intracranial artery stenosis. Arch Neurol. 2008;65(6):733–7. https://doi.org/10.1001/archneur.65.6.733.

    Article  PubMed  Google Scholar 

  36. Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology. 2006;66(8):1187–91. https://doi.org/10.1212/01.wnl.0000208404.94585.b2.

    Article  CAS  PubMed  Google Scholar 

  37. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383(9914):333–41. https://doi.org/10.1016/S0140-6736(13)62038-3.

    Article  PubMed  Google Scholar 

  38. • Planas-Ballvé A, Crespo AM, Aguilar LM, Hernández-Pérez M, Canento T, Dorado L, et al. The Barcelona-asymptomatic intracranial atherosclerosis study: subclinical intracranial atherosclerosis as predictor of long-term vascular events. Atherosclerosis. 2019;282:132–6. https://doi.org/10.1016/j.atherosclerosis.2019.01.022. A recent prospective study which shows that ICAS predicts vascular events in other arterial beds.

    Article  CAS  PubMed  Google Scholar 

  39. López-Cancio E, Dorado L, Millán M, Reverté S, Suñol A, Massuet A, et al. The population-based Barcelona-Asymptomatic Intracranial Atherosclerosis Study (ASIA): rationale and design. BMC Neurol. 2011;11:22. https://doi.org/10.1186/1471-2377-11-22.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol. 1998;55(11):1475–82. https://doi.org/10.1001/archneur.55.11.1475.

    Article  CAS  PubMed  Google Scholar 

  41. Chen XY, Wong KS, Lam WW, Zhao HL, Ng HK. Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study. Cerebrovasc Dis. 2008;25(1–2):74–80. https://doi.org/10.1159/000111525.

    Article  PubMed  Google Scholar 

  42. Amin-Hanjani S, Stapleton CJ, Du X, Rose-Finnell L, Pandey DK, Elkind MSV, et al. Hypoperfusion symptoms poorly predict hemodynamic compromise and stroke risk in Vertebrobasilar disease. Stroke. 2019;50(2):495–7. https://doi.org/10.1161/STROKEAHA.118.023101.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Liebeskind DS, Fong AK, Scalzo F, Lynn MJ, Derdeyn CP, Fiorella DJ, et al. The SAMMPRIS investigators. SAMMPRIS angiography discloses hemodynamic effects of intracranial stenosis: computational fluid dynamics of fractional flow. Stroke. 2013;44:A156.

    Google Scholar 

  44. Liebeskind DS, Cotsonis GA, Saver JL, Lynn MJ, Turan TN, Cloft HJ, et al. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. Ann Neurol. 2011;69(6):963–74. https://doi.org/10.1002/ana.22354.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Liebeskind DS, Kosinski AS, Lynn MJ, Scalzo F, Fong AK, Fariborz P, et al. Noninvasive fractional flow on MRA predicts stroke risk of intracranial stenosis. J Neuroimaging. 2015;25(1):87–91. https://doi.org/10.1111/jon.12101.

    Article  PubMed  Google Scholar 

  46. Khan A, Kasner SE, Lynn MJ, Chimowitz MI. Warfarin aspirin symptomatic intracranial disease (WASID) trial investigators. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke. 2012;43(5):1230–3. https://doi.org/10.1161/STROKEAHA.111.641696.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996;94(5):932–8. https://doi.org/10.1161/01.cir.94.5.932.

    Article  CAS  PubMed  Google Scholar 

  48. Chung GH, Kwak HS, Hwang SB, Jin GY. High resolution MR imaging in patients with symptomatic middle cerebral artery stenosis. Eur J Radiol. 2012;81(12):4069–74. https://doi.org/10.1016/j.ejrad.2012.07.001.

    Article  PubMed  Google Scholar 

  49. Zacharatos H, Hassan AE, Qureshi AI. Intravascular ultrasound: principles and cerebrovascular applications. AJNR Am J Neuroradiol. 2010;31(4):586–97. https://doi.org/10.3174/ajnr.A1810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Turan TN, Makki AA, Tsappidi S, Cotsonis G, Lynn MJ, Cloft HJ, et al. Risk factors associated with severity and location of intracranial arterial stenosis. Stroke. 2010;41(8):1636–40. https://doi.org/10.1161/STROKEAHA.110.584672.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Chimowitz MI, Lynn MJ, Turan TN, Fiorella D, Lane BF, Janis S, et al. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis. 2011;20(4):357–68. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.05.001.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017;88(4):379–85. https://doi.org/10.1212/WNL.0000000000003534.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Leung TW, Wang L, Soo YO, Ip VH, Chan AY, Au LW, et al. Evolution of intracranial atherosclerotic disease under modern medical therapy. Ann Neurol. 2015;77(3):478–86. https://doi.org/10.1002/ana.24340.

    Article  PubMed  Google Scholar 

  54. Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology. 2007;69(22):2063–8. https://doi.org/10.1212/01.wnl.0000279338.18776.26.

    Article  CAS  PubMed  Google Scholar 

  55. Mok VC, Lam WW, Chen XY, Wong A, Ng PW, Tsoi TH, et al. Statins for asymptomatic middle cerebral artery stenosis: the regression of cerebral artery stenosis study. Cerebrovasc Dis. 2009;28(1):18–25. https://doi.org/10.1159/000215939.

    Article  CAS  PubMed  Google Scholar 

  56. •• Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9. https://doi.org/10.1056/NEJMoa1910355. First randomized trial investigating different LDL-C targets in the secondary prophylaxis of non-cardioembolic stroke.

    Article  CAS  PubMed  Google Scholar 

  57. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

    Article  PubMed  Google Scholar 

  58. Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007;115(23):2969–75. https://doi.org/10.1161/CIRCULATIONAHA.106.622464.

    Article  PubMed  Google Scholar 

  59. Park JH, Ovbiagele B, Hong KS, Kwon SU. Association of systolic blood pressure with progression of symptomatic intracranial atherosclerotic stenosis. J Stroke. 2017;19(3):304–11. https://doi.org/10.5853/jos.2017.00136.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236. https://doi.org/10.1161/STR.0000000000000024.

    Article  PubMed  Google Scholar 

  61. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339.

    Article  PubMed  Google Scholar 

  62. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. Physical activity guidelines for Americans. JAMA. 2018;320(19):2020–8. https://doi.org/10.1001/jama.2018.14854.

    Article  PubMed  Google Scholar 

  63. Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(8):2532–53. https://doi.org/10.1161/STR.0000000000000022.

    Article  PubMed  Google Scholar 

  64. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology. 1995;45(8):1488–93. https://doi.org/10.1212/wnl.45.8.1488.

    Article  CAS  PubMed  Google Scholar 

  65. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology. 2000;55(4):490–7. https://doi.org/10.1212/wnl.55.4.490.

    Article  CAS  PubMed  Google Scholar 

  66. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–51. https://doi.org/10.1056/NEJMoa011258.

    Article  CAS  PubMed  Google Scholar 

  67. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305–16. https://doi.org/10.1056/NEJMoa043033.

    Article  CAS  PubMed  Google Scholar 

  68. Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS, et al. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology. 2006;67(7):1275–8. https://doi.org/10.1212/01.wnl.0000238506.76873.2f.

    Article  CAS  PubMed  Google Scholar 

  69. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489–97. https://doi.org/10.1016/S1474-4422(10)70060-0.

    Article  CAS  PubMed  Google Scholar 

  70. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240–8. https://doi.org/10.1001/jama.2015.1693.

    Article  CAS  PubMed  Google Scholar 

  71. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782–6. https://doi.org/10.1161/01.STR.0000157667.06542.b7.

    Article  CAS  PubMed  Google Scholar 

  72. • Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019;18(6):539–48. https://doi.org/10.1016/S1474-4422(19)30148-6. A randomized trial showing a significant benefit of adding cilostazol to aspirin or clopidogrel in the secondary prevention of non-cardioembolic stroke. 30% of the study-population had ICAS.

    Article  CAS  PubMed  Google Scholar 

  73. Aoki J, Iguchi Y, Urabe T, Yamagami H, Todo K, Fujimoto S, et al. Acute aspirin plus Cilostazol dual therapy for Noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. 2019;8(15):e012652. https://doi.org/10.1161/JAHA.119.012652.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–9. https://doi.org/10.1056/NEJMoa1215340.

    Article  CAS  PubMed  Google Scholar 

  75. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85(13):1154–62. https://doi.org/10.1212/WNL.0000000000001972.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Hong KS, Lee SH, Kim EG, Cho KH, Chang DI, Rha JH, et al. Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stroke. 2016;47(9):2323–30. https://doi.org/10.1161/STROKEAHA.115.012293.

    Article  CAS  PubMed  Google Scholar 

  77. Saraiva JFK. Stroke prevention with oral anticoagulants: summary of the evidence and efficacy measures as an aid to treatment choices. Cardiol Ther. 2018;7(1):15–24. https://doi.org/10.1007/s40119-018-0106-1.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Sundt TM Jr, Smith HC, Campbell JK, Vlietstra RE, Cucchiara RF, Stanson AW. Transluminal angioplasty for basilar artery stenosis. Mayo Clin Proc. 1980;55(11):673–80.

    PubMed  Google Scholar 

  79. Feldman RL, Trigg L, Gaudier J, Galat J. Use of coronary Palmaz-Schatz stent in the percutaneous treatment of an intracranial carotid artery stenosis. Catheter Cardiovasc Diagn. 1996;38(3):316–9. https://doi.org/10.1002/(SICI)1097-0304(199607)38:3<316::AID-CCD23>3.0.CO;2-D.

    Article  CAS  Google Scholar 

  80. SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke. 2004;35(6):1388–92. https://doi.org/10.1161/01.STR.0000128708.86762.d6.

    Article  Google Scholar 

  81. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375531, last access 28.01.2020.

  82. Bose A, Hartmann M, Henkes H, Liu HM, Teng MM, Szikora I, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the wingspan study. Stroke. 2007;38(5):1531–7. https://doi.org/10.1161/STROKEAHA.106.477711.

    Article  CAS  PubMed  Google Scholar 

  83. Fiorella D, Derdeyn CP, Lynn MJ, Barnwell SL, Hoh BL, Levy EI, et al. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS). Stroke. 2012;43(10):2682–8. https://doi.org/10.1161/STROKEAHA.112.661173.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Derdeyn CP, Fiorella D, Lynn MJ, Barnwell SL, Zaidat OO, Meyers PM, et al. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J Neurointerv Surg. 2013;5(6):528–33. https://doi.org/10.1136/neurintsurg-2012-010504.

    Article  PubMed  Google Scholar 

  85. •• Alexander MJ, Zauner A, Chaloupka JC, Baxter B, Callison RC, Gupta R, et al. WEAVE trial: final results in 152 on-label patients. Stroke. 2019;50(4):889–94. https://doi.org/10.1161/STROKEAHA.118.023996. Postmarket surveillance trial showing a low peri-interventional stroke-rate in symptomatic high-grade ICAS in carefully selected patients treated with the wing-span system, after narrowing the FDA approval criteria following the SAMMPRIS-results.

    Article  PubMed  Google Scholar 

  86. Gao P, Jiao L, Ma Y, Wang Y, Chen Y, Zhao Z, et al. Abstract 64: China angioplasty and stenting for symptomatic intracranial severe stenosis (CASSISS): a prospective, multicenter, randomized controlled trial after SAMMPRIS. Stroke. 49:A64. https://doi.org/10.1161/str.49.suppl_1.64. A multicenter trial comparing best medical treatment with best medical treatment and stenting with carefully patient-selection, based on the pitfalls of SAMMPRIS-trial.

  87. Markus HS, Larsson SC, Kuker W, Schulz UG, Ford I, Rothwell PM, et al. Stenting for symptomatic vertebral artery stenosis: the vertebral artery ischaemia stenting trial. Neurology. 2017;89(12):1229–36. https://doi.org/10.1212/WNL.0000000000004385.

    Article  PubMed  PubMed Central  Google Scholar 

  88. •• Miao Z, Song L, Liebeskind DS, Liu L, Ma N, Wang Y, et al. Outcomes of tailored angioplasty and/or stenting for symptomatic intracranial atherosclerosis: a prospective cohort study after SAMMPRIS. J Neurointerv Surg. 2015;7(5):331–5. https://doi.org/10.1136/neurintsurg-2014-011109. A prospective study that shows a low periprocedural stroke rate in patients with symptomatic ICAS treated with tailored stenting-techniques and -devices according to the lesion type.

    Article  PubMed  Google Scholar 

  89. Mori T, Fukuoka M, Kazita K, Mori K. Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol. 1998;19(8):1525–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. • Kang DH, Yoon W. Current opinion on endovascular therapy for emergent large vessel occlusion due to underlying intracranial atherosclerotic stenosis. Korean J Radiol. 2019;20:739–48. https://doi.org/10.3348/kjr.2018.0809. A manuscript elucidating current opinion on endovascular therapy for large vessel occlusion related to ICAS.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Kawashima M, Rhoton AL Jr, Tanriover N, Ulm AJ, Yasuda A, Fujii K. Microsurgical anatomy of cerebral revascularization. Part I: anterior circulation. J Neurosurg. 2005;102:116–31. https://doi.org/10.3171/jns.2005.102.1.0116.

    Article  PubMed  Google Scholar 

  92. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med. 1985;313(19):1191–200. https://doi.org/10.1056/NEJM198511073131904.

    Article  Google Scholar 

  93. Powers WJ, Martin WRW, Herscovitch P, Raichle ME, Grubb RL. Extracranial-intracranial bypass surgery. Hemodynamic and metabolic effects. Neurology. 1984;34(9):1168–74. https://doi.org/10.1212/WNL.34.9.1168.

    Article  CAS  PubMed  Google Scholar 

  94. Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P. Reversal of focal "misery-perfusion syndrome" by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography. Stroke. 1981;12:454–9. https://doi.org/10.1161/01.STR.12.4.454.

    Article  CAS  PubMed  Google Scholar 

  95. Vorstrup S, Lassen NA, Henriksen L, Haase J, Lindewald H, Boyse G, et al. CBF before and after extracranial-intracranial bypass surgery in patients with ischemic cerebrovascular disease studied with 133Xe-inhalation tomography. Stroke. 1985;16:616–26. https://doi.org/10.1161/01.STR.16.4.616.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland

    Adrian Scutelnic MD & Mirjam R. Heldner MD, MSc

  2. Institute of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital and University of Bern, Bern, Switzerland

    Pasquale Mordasini MD, MSc & Marwan El-Koussy MD, MSc

  3. Department of Neurosurgery, Inselspital, University hospital and University of Bern, Bern, Switzerland

    David Bervini MD, MAdvSurg

Authors
  1. Adrian Scutelnic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasquale Mordasini MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Bervini MD, MAdvSurg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marwan El-Koussy MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mirjam R. Heldner MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mirjam R. Heldner MD, MSc.

Ethics declarations

Conflict of Interest

Co-authors did not report any potential conflicts of interests directly related to this manuscript. MR Heldner reports advisory board honoraria by AMGEN.

Human and Animal Rights and Informed Consent

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cerebrovascular Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scutelnic, A., Mordasini, P., Bervini, D. et al. Management of Symptomatic Intracranial Atherosclerotic Stenosis. Curr Treat Options Neurol 22, 21 (2020). https://doi.org/10.1007/s11940-020-00626-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-020-00626-4

Keywords

Search

Navigation